Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
January 10 2017 - 9:00AM
Business Wire
-Funds to support results-driven research and
community projects engaged in HIV cure activities-
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the
recipients of its HIV cure grants program, a fund totaling more
than $22 million, which will support 12 new HIV cure research
projects. These projects will be conducted by leading academic
institutions, non-profit organizations and community groups from
around the world, focusing on three key areas: translational
research, efficacy studies in animal models and community
perspectives of HIV cure.
“We know from decades of work addressing the issue of HIV/AIDS
that there is no one-size-fits-all solution. Through partnerships
with dedicated and results-driven organizations – such as the
worthy recipients of our grant funding – our goal is to help in the
discovery and development of a safe and effective cure,” said
William Lee, PhD, Executive Vice President, Research, Gilead
Sciences. “We are excited about the potential of these projects and
are looking forward to seeing the results and learnings that emerge
from them.”
The following institutions and corresponding projects will
receive funding to complete their research over the next three
years (Institution/Principal Investigator/Project Name):
- Massachusetts General Hospital – Galit
Alter, Ph.D. – Development of a Novel Class of Broadly Functional
Antibodies (bFAbs) That Can Kill the Viral Reservoir Within
Lymphoid Sanctuaries
- Fred Hutchinson Cancer Research Center
– Lawrence Corey, M.D. – Adoptive Transfer of Genetically Protected
and Genetically Modified Defined Populations of CAR T Cells as a
Modality to Achieve HIV-1 Cure
- Foundation for the National Institutes
of Health, National Cancer Institute, Center for Cancer Research –
George N. Pavlakis, M.D., Ph.D. – Efficacy of Heterodimeric IL-15
Treatment Regimens in Reducing SIV Reservoir
- Johns Hopkins University School of
Medicine – Robert Siliciano, M.D., Ph.D. – Measuring the Latent
Reservoir for HIV
- University of Zurich, Institute of
Medical Virology – Alexandra Trkola, Ph.D. – SEEK, UNCOVER and
ELIMINATE: Eliciting Antiviral and Infected Cell-Directed
Activities Towards a Cure of HIV-1
- Institut Pasteur – Olivier Schwartz,
Ph.D. – Novel Methods to Visualize and Eliminate the HIV-1
Reservoir
- Aarhus University Hospital – Ole
Schmeltz Sogaard, M.D., Ph.D. – Combining a TLR9 Agonist With
Broadly Neutralizing Antibodies for Viral Reservoir Reduction and
Immunological Control of HIV Infection: A Randomized,
Placebo-Controlled Trial
- University of KwaZulu-Natal – Thumbi
Ndung’u, Ph.D. – The FRESH Study: Females Rising Through Education,
Support and Health (‘FRESH’) Acute HIV Infection Cohort
- Case Western Reserve University School
of Medicine – Michael M. Lederman, M.D. – Reservoir Reduction with
Interleukin-2 and Transcriptional Activation
- AIDS Foundation of Chicago – Amy
Johnson, Ph.D. – Chicago Unites in Research to End HIV (CURE
HIV)
- Project Inform – David Evans – Assuring
Successful Community Participation in HIV Cure Research
- My Brother’s Keeper, Inc. – DeMarc
Hickson, Ph.D. – HIV Cure Research Perception Among HIV-Infected
African American MSM, and Affected Communities in the Deep American
South: A Multi-Level Mixed Methods Perspective
The HIV cure grants program, initially announced in February
2016, is one of the components of Gilead’s commitment to cure and
ultimately eradicate HIV and AIDS through its research and
development and philanthropic leadership.
For nearly 30 years, Gilead has focused on the development of
antiretroviral therapy to treat HIV/AIDS, helping transform HIV
infection from a fatal and debilitating disease into a chronic,
manageable condition. In further efforts to end the HIV epidemic,
Gilead is conducting early-stage clinical research to identify
novel agents and strategies that could play a role in eradicating
HIV infection in the body.
In addition to the funding of these grants, Gilead was recently
announced as one of the foremost corporate providers of
philanthropic support to address HIV/AIDS by the Funders Concerned
About AIDS (FCAA) organization.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170110005553/en/
Gilead Sciences, Inc.MediaNick Francis,
650-522-5674orInvestorsSung Lee, 650-524-7792
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024